Skip to content 
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. more
| Time Frame | BBLG | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -2.05% | 1.07% | 0.74% |
| 1-Month Return | -30.92% | 1.46% | 1.28% |
| 3-Month Return | -23.89% | 3.51% | 3.6% |
| 6-Month Return | -46.89% | 15.29% | 7.31% |
| 1-Year Return | -81.21% | 7.7% | 11.97% |
| 3-Year Return | -99.76% | 21.02% | 72.07% |
| 5-Year Return | -84.04% | 37.81% | 76.01% |
| 10-Year Return | -71.38% | 139.15% | 258.47% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 825.01K | 1.10M | 3.67M | 9.43M | 4.22M | [{"date":"2020-12-31","value":8.75,"profit":true},{"date":"2021-12-31","value":11.68,"profit":true},{"date":"2022-12-31","value":38.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":44.75,"profit":true}] |
| Operating Income | (825.01K) | (1.10M) | (3.67M) | (9.43M) | (4.22M) | [{"date":"2020-12-31","value":-82501400,"profit":false},{"date":"2021-12-31","value":-110147600,"profit":false},{"date":"2022-12-31","value":-366517300,"profit":false},{"date":"2023-12-31","value":-942800000,"profit":false},{"date":"2024-12-31","value":-421900000,"profit":false}] |
| Total Non-Operating Income/Expense | (2.00M) | (1.31M) | 1.45M | (250.62K) | 162.40K | [{"date":"2020-12-31","value":-137.78,"profit":false},{"date":"2021-12-31","value":-90.6,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-17.3,"profit":false},{"date":"2024-12-31","value":11.21,"profit":true}] |
| Pre-Tax Income | (1.82M) | (1.61M) | (1.48M) | (8.95M) | (4.11M) | [{"date":"2020-12-31","value":-182309000,"profit":false},{"date":"2021-12-31","value":-160908500,"profit":false},{"date":"2022-12-31","value":-148462000,"profit":false},{"date":"2023-12-31","value":-894900000,"profit":false},{"date":"2024-12-31","value":-411242000,"profit":false}] |
| Income Taxes | 1.60K | 1.60K | (2.18M) | (2.18M) | (7.32M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-136312.5,"profit":false},{"date":"2023-12-31","value":-136284.56,"profit":false},{"date":"2024-12-31","value":-457807.75,"profit":false}] |
| Income After Taxes | (1.82M) | (1.61M) | 696.38K | (6.77M) | 3.21M | [{"date":"2020-12-31","value":-56.8,"profit":false},{"date":"2021-12-31","value":-50.14,"profit":false},{"date":"2022-12-31","value":21.68,"profit":true},{"date":"2023-12-31","value":-210.69,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income From Continuous Operations | (1.82M) | (1.61M) | (1.48M) | (6.51M) | (4.11M) | [{"date":"2020-12-31","value":-182469000,"profit":false},{"date":"2021-12-31","value":-161068500,"profit":false},{"date":"2022-12-31","value":-148462000,"profit":false},{"date":"2023-12-31","value":-650538600,"profit":false},{"date":"2024-12-31","value":-411242000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (1.82M) | (1.61M) | (1.48M) | (8.95M) | (4.11M) | [{"date":"2020-12-31","value":-182469000,"profit":false},{"date":"2021-12-31","value":-161068500,"profit":false},{"date":"2022-12-31","value":-148462000,"profit":false},{"date":"2023-12-31","value":-894900000,"profit":false},{"date":"2024-12-31","value":-411200000,"profit":false}] |
| EPS (Diluted) | (731.35) | (0.35) | (0.42) | (10.46) | (19.08) | [{"date":"2020-12-31","value":-73134.59,"profit":false},{"date":"2021-12-31","value":-35,"profit":false},{"date":"2022-12-31","value":-42,"profit":false},{"date":"2023-12-31","value":-1046,"profit":false},{"date":"2024-12-31","value":-1908,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BBLG | |
|---|---|
| Cash Ratio | 18.10 |
| Current Ratio | 19.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BBLG | |
|---|---|
| ROA (LTM) | -48.68% |
| ROE (LTM) | -80.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BBLG | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BBLG | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.36 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | 0.13 |
| PEG | NM |
Bone Biologics Corp (BBLG) share price today is $1.2
Yes, Indians can buy shares of Bone Biologics Corp (BBLG) on Vested. To buy
Yes, you can purchase fractional shares of Bone Biologics Corp (BBLG) via the Vested app. You can start investing in Bone Biologics Corp (BBLG) with a minimum investment of $1.
You can invest in shares of Bone Biologics Corp (BBLG) via Vested in three simple steps:
The 52-week high price of Bone Biologics Corp (BBLG) is $6.75. The 52-week low price of Bone Biologics Corp (BBLG) is $1.11.
The price-to-earnings (P/E) ratio of Bone Biologics Corp (BBLG) is
The price-to-book (P/B) ratio of Bone Biologics Corp (BBLG) is 0.36
The dividend yield of Bone Biologics Corp (BBLG) is 0.00%
The market capitalization of Bone Biologics Corp (BBLG) is $2.15M
The stock symbol (or ticker) of Bone Biologics Corp is BBLG
Consider the share price of Bone Biologics Corp as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Bone Biologics Corp has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Bone Biologics Corp shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Bone Biologics Corp stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Bone Biologics Corp and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Bone Biologics Corp stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
